ICJIM
Intercontinental Journal of Internal Medicine

The Intercontinental Journal of Internal Medicine aims to publish issues related to all fields of internal medicine of the highest scientific and clinical value at an international level and accepts articles on these topics. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

eISSN: 2980-0846
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Review
A look at common gastrointestinal system diseases: current review
Abstract
The gastrointestinal system consists of the esophagus, stomach, small intestine, large intestine, and rectum. Although they are called accessory organs, the liver, pancreas, and gallbladder are also evaluated in this system with their vital features. Gastrointestinal system disorders (GISD) are observed quite frequently in society. Considering the morbidity and mortality they cause, effective treatment methods become crucial. Situations such as patients’ non-compliance with nutritional recommendations and the inadequacy of pharmacological and surgical methods at some points make different perspectives and treatment methods more valuable. From this point of view, we will try to examine the GISD that causes muscle loss and the physiotherapy modalities that can be applied to these patients in light of the current literature.

Keywords : Gastrointestinal system, physiotherapy, role

Download Article


1. Lee YT, Sung JJ. Protein-losing enteropathy. Gastrointest Endosc.2004;60(5):801-802. doi:10.1016/s0016-5107(04)02025-5
2. Schmidt PN, Blirup-Jensen S, Svendsen PJ, Wandall JH.Characterization and quantification of plasma proteins excreted infaeces from healthy humans. Scand J Clin Lab Invest. 1995;55(1):35-45.doi:10.3109/00365519509075376
3. Meadows J, Jenkins K. Protein-losing enteropathy: integrating a newdisease paradigm into recommendations for prevention and treatment.Cardiol Young. 2011;21(4):363-377. doi:10.1017/S1047951111000102
4. Schmalzle SA, Wolde-Rufael D, Gilliam BL. Photo quiz. Diarrhea,anasarca, and severe hypoalbuminemia in an AIDS patient. Diagnosis:AIDS-related visceral Kaposi sarcoma (KS) with protein-losingenteropathy (PLE). Clin Infect Dis. 2015;60(8):1241-1283. doi:10.1093/cid/ciu963
5. Elli L, Topa M, Rimondi A. Protein-losing enteropathy. Curr OpinGastroenterol. 2020;36(3):238-244. doi:10.1097/MOG.0000000000000629
6. Müller C, Globits S, Glogar D, Klepetko W, Knoflach P. Constrictivepericarditis without typical haemodynamic changes as a cause ofoedema formation due to protein-losing enteropathy. Eur Heart J.1991;12(10):1140-1143. doi:10.1093/oxfordjournals.eurheartj.a059848
7. Lee HJ, Rha MY, Cho YY, Kim ER, Chang DK. A case of proteinsupplement effect in protein-losing enteropathy. Clin Nutr Res.2012;1(1):94-98. doi:10.7762/cnr.2012.1.1.94
8. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification ofCrohn’s disease: report of the Working Party for the World Congressesof Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6(1):8-15.doi:10.1097/00054725-200002000-00002
9. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence andprevalence of the inflammatory bowel diseases with time, based onsystematic review. Gastroenterology. 2012;142(1):46-e30. doi:10.1053/j.gastro.2011.10.001
10. Collen LV, Kim DY, Field M, et al. Clinical phenotypes and outcomes inmonogenic versus non-monogenic very early onset inflammatory boweldisease. J Crohns Colitis. 2022;16(9):1380-1396. doi:10.1093/ecco-jcc/jjac045
11. Amre DK, D’Souza S, Morgan K, et al. Imbalances in dietaryconsumption of fatty acids, vegetables, and fruits are associatedwith risk for Crohn’s disease in children. Am J Gastroenterol.2007;102(9):2016-2025. doi:10.1111/j.1572-0241.2007.01411.x
12. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical,molecular and serological classification of inflammatory bowel disease:report of a Working Party of the 2005 Montreal World Congress ofGastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A-36A.doi:10.1155/2005/269076
13. Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, Powell DW, YamadaT. Textbook of gastroenterology: John Wiley & Sons; 2011.
14. Monsén U, Sorstad J, Hellers G, Johansson C. Extracolonic diagnosesin ulcerative colitis: an epidemiological study. Am J Gastroenterol.1990;85(6):711-716.
15. Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinicalfeatures and natural history of Crohn’s disease. Gastroenterology.1979;77(4 Pt 2):898-906.
16. D’Haens G, Baert F, van Assche G, et al. Early combinedimmunosuppression or conventional management in patients withnewly diagnosed Crohn’s disease: an open randomised trial. Lancet.2008;371(9613):660-667. doi:10.1016/S0140-6736(08)60304-9
17. Caldwell SH, Crespo DM. The spectrum expanded: cryptogeniccirrhosis and the natural history of non-alcoholic fatty liver disease. JHepatol. 2004;40(4):578-584. doi:10.1016/j.jhep.2004.02.013
18. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalenceof the most common causes of chronic liver diseases in the UnitedStates from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524-e60. doi:10.1016/j.cgh.2011.03.020
19. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH,Driscoll CJ. Cryptogenic cirrhosis: clinical characterization andrisk factors for underlying disease. Hepatology. 1999;29(3):664-669.doi:10.1002/hep.510290347
20. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis andmanagement of non-alcoholic fatty liver disease: practice Guidelineby the American Association for the Study of Liver Diseases,American College of Gastroenterology, and the AmericanGastroenterological Association. Hepatology. 2012;55(6):2005-2023.doi:10.1002/hep.25762
21. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, SchickF. Non-invasive assessment and quantification of liver steatosis byultrasound, computed tomography and magnetic resonance. J Hepatol.2009;51(3):433-445. doi:10.1016/j.jhep.2009.05.023
22. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physicalactivity in overweight patients with chronic liver disease results insustained improvements in alanine aminotransferase, fasting insulin,and quality of life. Gut. 2004;53(3):413-419. doi:10.1136/gut.2003.027581
23. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis inchildren: a pilot study. J Pediatr. 2000;136(6):734-738.
24. Wasley A, Grytdal S, Gallagher K. Surveillance for acute viralhepatitis--United States, 2006. Morbidity and mortality weekly reportSurveillance summaries (Washington, DC : 2002). 2008;57(2):1-24.
25. Liaw YF, Tsai SL, Sheen IS, et al. Clinical and virological courseof chronic hepatitis B virus infection with hepatitis C and D virusmarkers. Am J Gastroenterol. 1998;93(3):354-359. doi:10.1111/j.1572-0241.1998.00354.x
26. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronichepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521-1531. doi:10.1056/NEJMoa033364
27. Testing for HCV infection: an update of guidance for cliniciansand laboratorians. MMWR Morbidity and mortality weekly report.2013;62(18):362-5.
28. Chan HL, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ. Long-termfollow-up of peginterferon and lamivudine combination treatment inHBeAg-positive chronic hepatitis B. Hepatology. 2005;41(6):1357-1364.doi:10.1002/hep.20695
29. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis isthe second leading etiology of liver disease among adults awaiting livertransplantation in the United States. Gastroenterology. 2015;148(3):547-555. doi:10.1053/j.gastro.2014.11.039
30. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I.Diagnosis and evaluation. Am Fam Physician. 2006;74(5):756-762.
31. Dirchwolf M, Podhorzer A, Marino M, et al. Immune dysfunction incirrhosis: Distinct cytokines phenotypes according to cirrhosis severity.Cytokine. 2016;77:14-25. doi:10.1016/j.cyto.2015.10.006
32. Burra P, Germani G, Masier A, et al. Sexual dysfunction in chronicliver disease: is liver transplantation an effective cure?. Transplantation.2010;89(12):1425-1429. doi:10.1097/TP.0b013e3181e1f1f6
33. Pirovino M, Linder R, Boss C, Köchli HP, Mahler F. Cutaneousspider nevi in liver cirrhosis: capillary microscopical and hormonalinvestigations. Klin Wochenschr. 1988;66(7):298-302. doi:10.1007/BF01727516
34. Cattau EL Jr, Benjamin SB, Knuff TE, Castell DO. The accuracy of thephysical examination in the diagnosis of suspected ascites. JAMA.1982;247(8):1164-1166.
35. Udell JA, Wang CS, Tinmouth J, et al. Does this patient with liver diseasehave cirrhosis?. JAMA. 2012;307(8):832-842. doi:10.1001/jama.2012.186
36. Hézode C, Castéra L, Roudot-Thoraval F, et al. Liver stiffness diminisheswith antiviral response in chronic hepatitis C. Aliment Pharmacol Ther.2011;34(6):656-663. doi:10.1111/j.1365-2036.2011.04765.x
37. Steer ML, Waxman I, Freedman S. Chronic pancreatitis. N Engl J Med.1995;332(22):1482-1490. doi:10.1056/NEJM199506013322206
38. Yadav D, Hawes RH, Brand RE, et al. Alcohol consumption,cigarette smoking, and the risk of recurrent acute and chronicpancreatitis. Arch Intern Med. 2009;169(11):1035-1045. doi:10.1001/archinternmed.2009.125
39. Freedman SD, Sakamoto K, Venu RP. GP2, the homologue to the renalcast protein uromodulin, is a major component of intraductal plugsin chronic pancreatitis. J Clin Invest. 1993;92(1):83-90. doi:10.1172/JCI116602
40. Ammann RW, Muellhaupt B. The natural history of pain in alcoholicchronic pancreatitis. Gastroenterology. 1999;116(5):1132-1140. doi:10.1016/s0016-5085(99)70016-8
41. Mergener K, Baillie J. Chronic pancreatitis. Lancet. 1997;350(9088):1379-1385. doi:10.1016/S0140-6736(97)07332-7
42. Luetmer PH, Stephens DH, Ward EM. Chronic pancreatitis:reassessment with current CT. Radiology. 1989;171(2):353-357.doi:10.1148/radiology.171.2.2704799.
43. Shea JC, Bishop MD, Parker EM, Gelrud A, Freedman SD. An enteraltherapy containing medium-chain triglycerides and hydrolyzedpeptides reduces postprandial pain associated with chronicpancreatitis. Pancreatology. 2003;3(1):36-40. doi:10.1159/000069144
44. Leung JW, Bowen-Wright M, Aveling W, Shorvon PJ, Cotton PB.Coeliac plexus block for pain in pancreatic cancer and chronicpancreatitis. Br J Surg. 1983;70(12):730-732. doi:10.1002/bjs.1800701212
45. Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ 3rd. Epidemiology ofcolonic symptoms and the irritable bowel syndrome. Gastroenterology.1991;101(4):927-934. doi:10.1016/0016-5085(91)90717-y
46. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey offunctional gastrointestinal disorders. Prevalence, sociodemography,and health impact. Dig Dis Sci. 1993;38(9):1569-1580. doi:10.1007/BF01303162
47. American College of Gastroenterology Task Force on Irritable BowelSyndrome, Brandt LJ, Chey WD, et al. An evidence-based positionstatement on the management of irritable bowel syndrome. Am JGastroenterol. 2009;104 Suppl 1:S1-S35. doi:10.1038/ajg.2008.122
48. Hahn BA, Saunders WB, Maier WC. Differences between individualswith self-reported irritable bowel syndrome (IBS) and IBS-like symptoms.Dig Dis Sci. 1997;42(12):2585-2590. doi:10.1023/a:1018889318063
49. Saito YA, Locke GR, Talley NJ, Zinsmeister AR, Fett SL, MeltonLJ 3rd. A comparison of the Rome and Manning criteria for caseidentification in epidemiological investigations of irritable bowelsyndrome. Am J Gastroenterol. 2000;95(10):2816-2824. doi:10.1111/j.1572-0241.2000.03192.x
50. Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functionalgastrointestinal disorders in Canada: first population-based surveyusing Rome II criteria with suggestions for improving the questionnaire.Dig Dis Sci. 2002;47(1):225-235. doi:10.1023/a:1013208713670
51. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patternsand impact of irritable bowel syndrome: an international surveyof 40,000 subjects. Aliment Pharmacol Ther. 2003;17(5):643-650.doi:10.1046/j.1365-2036.2003.01456.x
52. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowelsyndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-721.e4. doi:10.1016/j.cgh.2012.02.029
53. Longstreth GF, Thompson WG, Chey WD, Houghton LA, MearinF, Spiller RC. Functional bowel disorders. Gastroenterology.2006;130(5):1480-1491. doi:10.1053/j.gastro.2005.11.061
54. Swarbrick ET, Hegarty JE, Bat L, Williams CB, Dawson AM. Site of painfrom the irritable bowel. Lancet. 1980;2(8192):443-446. doi:10.1016/s0140-6736(80)91885-1
55. Manning AP, Thompson WG, Heaton KW, Morris AF. Towardspositive diagnosis of the irritable bowel. Br Med J. 1978;2(6138):653-654. doi:10.1136/bmj.2.6138.653
Article available in :
Volume 1, Issue 2, 2023
Page : 50-56
https://doi.org/10.51271/ICJIM-0010
Article Information
Received : 17 May 2023
Accepted : 26 May 2023
Published : 29 May 2023
Corresponding Author :

İhsan Solmaz: Department of Internal Medicine, Gazi Yaşargil Training and Research Hospital, Health Sciences University, Diyarbakır, Turkiye

[email protected]
Citation : Tekin Y, Başgöz BB, Solmaz İ. A look at common gastrointestinal system diseases: current review. Intercont J Int Med. 2023;1(2):50-56.

Read: 523
Cited: 0
Download : 218
_Footer